Pandemic-led supply chain disruption continues to threaten CDMO activity. How can the industry overcome and maybe even thrive? I explore just that.
The pharmaceutical climate is changing to focus patient care in care development. How are small companies thriving in this space? Here, I discuss just that.
As the alternative protein market grows, how can we optimise cultured meat production for continued success and sustainability? These industry leaders are showing the way.
.jpg)
Bioinformatic development is changing the way we work. With funding developments and technology advancements expected, who should we be watching in 2023 and beyond?
Talent scarcity is hard to solve in the current climate, but developing a strategy of substance for attracting top-tier candidates is the ultimate way to stand out and win the right people. Here, I delve into how to do just that.
In an ever-changing industry, how can cell and gene therapy start-ups remain dynamic to new challenges to not only survive coming changes but thrive? Click to read more.
The data revolution has created a wealth of opportunity in the bioinformatics industry. I caught up with three industry experts to find out what's next for software data in the life sciences industry. Click to find out who.
Developing and manufacturing drugs is more expensive and complicated than ever before. Many outsource to CDMO's, but which approach truly offers the most value? Click to read more.
In part two of this discussion, Dennis and I discuss the key barriers for entry for companies expanding into new territories and how to overcome these, whether you're a start-up or established company entering a new market. Click to listen.
Predicine With a background in research, pharma and commercial, Dennis gives insight into the true value of liquid biopsy. Click to listen.
We talk to Tim Roberts, who’s Chief Commercial Officer at PCI Pharma Services. Click to listen to his experiences in and predictions for the clinical trial supply market.
Cannabis legalisation is the hot topic of many European politicians, but once the race begins who will be in it to win? Click to read more.
.jpg)
In pharma packaging and drug delivery, everyone is beginning to talk about sustainability again. How can we meet this increasing demand without causing further harm to our environment? Click to read about 5 companies embracing change.
In the US, New Jersey is a life science powerhouse. It’s home to some of the most influential pharma manufacturers in the world. Click to find out some of the latest developments coming from this area.
I come across different exciting companies every day. Each has their own unique story and innovative treatments to match. Click for five companies who’s work you need to know about.
Pharma packaging is embracing digital health to become smarter and safer. I wanted to highlight some of the exciting developments that are integrating the use of digital technology within the healthcare sectors and the companies involved.
.jpg)
There’s optimism throughout all the markets we serve and to celebrate this we asked our CM Life Science team what they think we can expect from the year ahead in life sciences. Here's what they said...
We are undergoing the biggest vaccination program in history, aiming to finally bring the COVID-19 pandemic to an end. This presents pharmacovigilance’s with its biggest test yet.
To gain further insight into how labs have adapted, the CM Life Science team spoke to three North American market leaders in laboratory testing services about how they’ve supported the US healthcare system.
In this episode, we delved into the Life Science space for a conversation with Mark Rohlfing and Natalie Balanovsky from international pharmaceutical business, Almac.
In the US alone, a report by the Centers for Disease Control and Prevention (CDC) in March this year highlighted how 2.8 million antibiotic-resistant infections occur each year, leading to the deaths of more than 35,000 people.
.png)
Billions of dollars have been pumped into medicinal cannabis. It’s popular with patients. The public’s perceptions are changing (for the better) and the competition isn’t nearly as tough as other markets in pharmaceuticals.
.png)
Decentralised, virtual, home, remote… whatever the name of this type of trial, it's widely agreed they will be crucial to advancing healthcare.
Pharma packaging is in transition. Companies are now pushing boundaries, furthering their offerings and innovating to be seen as true healthcare partners.
In the last decade, the amount of medical data we have access to has exploded. So much so that just interpreting, processing and gaining insights from this data has turned into a whole new area of study and investment - bioinformatics.
It’s no secret that plastic is in the global bad books at the moment, thanks to admissions like Coca Cola’s last year, that they produced over 3m tonnes of plastic packaging in 2017. That works out at 200,000 bottles a minute.
It’s hard to estimate the total size and value of the diagnostics market, however by looking at some of the forecasts available, the scale of the industry is evident.
If one of the global pharma giants develops a new blockbuster drug, they can’t just ship it. They need to perform extensive testing.
There’s always a ‘next big thing’ in the healthcare, research and life sciences industries but the emergence and development of the biotech sector is one of the few that has the chance to change the world.
When I first made the decision to write an article about CRO size and what impact it has on service, the idea revolved around a ‘David vs Goliath’ narrative. I was going to write about major CROs compared to smaller CROs, then (spoiler alert) come...
